Corcept Therapeutics Incorporated (NASDAQ:CORT) currently has a daily average trading volume of 568.75K but it saw 322071 shares traded on Wednesday. With a market cap of 2.74B USD, stock’s current market price of $25.99 came falling about -0.19 while comparing to the previous closing price of $26.04. In past 52 weeks, the stock remained buoying in the range of price level as high as $30.14 and as low as $15.82.
Taking a look at 20-day trading activity of Corcept Therapeutics Incorporated (CORT) gives us an average price of $26.69, while its current price level is -13.77% below from 52-week high level whereas it is 64.23% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $26.62 while that of 200 days or SMA-200 reads an average of $24.62. A closer look into the stock’s movement over the week reveals that its volatility is standing at 2.64% during that period while stretching the period over a month that increases to 4.28%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 45.88 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Truist which downgraded the stock as “Hold” in its note to investors issued on August 01, 2022, recommending a price target of $30 for it. Jefferies upgraded its recommendation for the stock as a “Buy” from “Hold” on July 27, 2022 while assigning a price target range of $21-$35. Canaccord Genuity issued its recommendations for the stock as it resumed the price target for the stock in the range of between $30 and $34.
Over the week, CORT’s stock price is moving -1.59% down while it is -8.29% when we observe its performance for the past one month. Year-to-date it is 31.26% up and over the past year, the stock is showing an upside performance of 15.56%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2022, when its quarterly earnings per share (EPS) of $0.24 beat the consensus estimate of $0.23 for the same. The company is expected to be releasing its next quarterly report in 02/14/2023, for which analysts forecasted an EPS of $0.22 while estimate for next year EPS is $0.89. In next quarter, company is expected to be making quarterly sales of $112.04 million as analysts are expecting the sales for current fiscal year at $416.67 million and seeing the company making $463.21 million in sales next year. Moreover, analysts are in estimates of $107.59 million for current-quarter revenue.
Currently, Corcept Therapeutics Incorporated’s total number of outstanding shares is 107.12M with 11.18% of that held by the insiders while 80.52% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 29.80% and return on equity (ROE) at 27.50%. It has a price to earnings ratio (P/E ratio) of 26.15 while having a 26.85 of forward P/E ratio. Stock’s beta reads 0.56. Stock has a price to book (P/B) ratio of 5.88 while price to sale or P/S ratio amounts to 6.89. Its return on asset (ROA) is 24.30% on average.
A filing at the U.S. Securities and Exchange Commission revealed that iShares Core S&P Small Cap ETF came shrinking its share ownership by 0.07% in the Corcept Therapeutics Incorporated (CORT) increasing its stake to 6.59% with control over 4616.0 shares in the company. In the most recent quarter, Vanguard Total Stock Market Index came rising its stake by 0.39% in the company and now holds 2.75 million or 2.56% of the company’s stake having worth of about 78.52 million.